HK1110207A1 - Ophthalmic compositions and methods of using the same - Google Patents

Ophthalmic compositions and methods of using the same

Info

Publication number
HK1110207A1
HK1110207A1 HK08100863.6A HK08100863A HK1110207A1 HK 1110207 A1 HK1110207 A1 HK 1110207A1 HK 08100863 A HK08100863 A HK 08100863A HK 1110207 A1 HK1110207 A1 HK 1110207A1
Authority
HK
Hong Kong
Prior art keywords
methods
ophthalmic compositions
compositions
ketotifen
same
Prior art date
Application number
HK08100863.6A
Other languages
English (en)
Inventor
Kenneth E Green
George E Minno
Susan Caballa
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/972,571 external-priority patent/US20060089384A1/en
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of HK1110207A1 publication Critical patent/HK1110207A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
HK08100863.6A 2004-10-25 2008-01-23 Ophthalmic compositions and methods of using the same HK1110207A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/972,571 US20060089384A1 (en) 2004-10-25 2004-10-25 Ophthalmic compositions and methods of using the same
US62375804P 2004-10-29 2004-10-29
PCT/US2005/038186 WO2006047418A1 (en) 2004-10-25 2005-10-24 Ophthalmic compositions and methods of using the same

Publications (1)

Publication Number Publication Date
HK1110207A1 true HK1110207A1 (en) 2008-07-11

Family

ID=36228119

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100863.6A HK1110207A1 (en) 2004-10-25 2008-01-23 Ophthalmic compositions and methods of using the same

Country Status (14)

Country Link
US (2) US20060148899A1 (xx)
EP (1) EP1845983B1 (xx)
JP (1) JP4980226B2 (xx)
KR (1) KR101252310B1 (xx)
CN (1) CN101087607B (xx)
AT (1) ATE463244T1 (xx)
AU (1) AU2005299696B2 (xx)
BR (1) BRPI0517451A (xx)
CA (1) CA2585266C (xx)
DE (1) DE602005020513D1 (xx)
ES (1) ES2341789T3 (xx)
HK (1) HK1110207A1 (xx)
MX (1) MX2007004905A (xx)
WO (1) WO2006047418A1 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208058A1 (en) * 2004-10-25 2007-09-06 Bryant Roy W Stable Pharmaceutical Compositions and Methods of Making and Using Same
US20090005362A1 (en) * 2007-06-26 2009-01-01 Vo Toan P Compositions Comprising Antihistamines or Mast Cell Stabilizers, and Methods of Making and Using Same
RU2600863C2 (ru) * 2007-12-10 2016-10-27 Сентисс Фарма Прайвит Лимитед Офтальмическая композиция, включающая фенилэфрин
US20100087550A1 (en) 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
US8741930B2 (en) * 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
JP2012520880A (ja) * 2009-03-17 2012-09-10 アーシエックス セラピューティックス， インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
JP7014508B2 (ja) 2016-08-08 2022-02-01 シャープ株式会社 自律走行装置及び自律走行制御方法と制御プログラム
WO2024028816A1 (en) 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising pilocarpine and a redness reduction agent
US20240041869A1 (en) 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising an anti-allergen and a redness reduction agent

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US4826871A (en) * 1985-03-13 1989-05-02 Gressel Philip D Topical ophthalmic compositions containing one or more retinoids
JPS62277323A (ja) * 1986-02-19 1987-12-02 Sankyo Co Ltd フマル酸ケトチフエン含有点眼液の製法
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
ID26033A (id) * 1998-04-02 2000-11-16 Novartis Ag Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
US6777429B1 (en) * 1999-07-23 2004-08-17 Novartis Ag Ophthalmic composition
US20040097486A1 (en) * 1999-11-18 2004-05-20 Yanni John M. Use of an H1 antagonist and a safe steroid to treat eye conditions
AU772406B2 (en) * 1999-11-18 2004-04-29 Alcon Inc. Use of H1 antagonist and a safe steroid to treat eye conditions
US6395756B2 (en) * 1999-12-23 2002-05-28 Novartis Ag Use of ophthalmic agent
US6531128B1 (en) * 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6515006B2 (en) * 2000-11-08 2003-02-04 Hmt Pharma, Inc. Ophthalmic formulation which modulates dilation
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2004069157A2 (en) * 2003-01-17 2004-08-19 Ophthalmic Research Associates, Inc. Combinational use of long-acting and short-acting anti-histamines for ocular allergies

Also Published As

Publication number Publication date
AU2005299696B2 (en) 2012-01-12
MX2007004905A (es) 2007-10-15
DE602005020513D1 (de) 2010-05-20
CA2585266A1 (en) 2006-05-04
ES2341789T3 (es) 2010-06-28
CN101087607B (zh) 2010-07-28
CN101087607A (zh) 2007-12-12
CA2585266C (en) 2010-10-19
US20120004265A1 (en) 2012-01-05
WO2006047418A1 (en) 2006-05-04
ATE463244T1 (de) 2010-04-15
JP4980226B2 (ja) 2012-07-18
KR101252310B1 (ko) 2013-04-08
BRPI0517451A (pt) 2008-10-07
KR20070074635A (ko) 2007-07-12
US20060148899A1 (en) 2006-07-06
EP1845983A4 (en) 2008-03-12
EP1845983A1 (en) 2007-10-24
EP1845983B1 (en) 2010-04-07
AU2005299696A1 (en) 2006-05-04
JP2008517937A (ja) 2008-05-29

Similar Documents

Publication Publication Date Title
HK1110207A1 (en) Ophthalmic compositions and methods of using the same
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE494893T1 (de) Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
MX2007004264A (es) Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares.
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
ATE368031T1 (de) Neue gamma secretase inhibitoren
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
WO2005123093A3 (en) Ophthalmic formulations including selective alpha 1 antagonists
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
DE60126947D1 (de) Behandlung der glykogenspeicherkrankheit typ ii
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
ATE451361T1 (de) Materialien und methoden zur behandlung von koagulationsstörungen
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
TR200400526T4 (tr) Göz kurumasının tedavisi için lipoksin A4 ve analogları